Cohen Children's Medical Center

Running trials

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

  NCT06271512· Genetix Biotherapeutics Inc.· Source

• Active, not recruiting

  Eatable Alphabet as a Nutrition Education Tool

  NCT05166629· Northwell Health· Source

• Recruiting

  Dynamic Critical Congenital Heart Screening With Addition of Perfusion Measurements

  NCT05637814· University of California, Davis· Source

• Enrolling by invitation

  Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

  NCT05844449· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· PedAL BCU, LLC· Source

• Active, not recruiting

  Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

  NCT05422222· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

  NCT05199272· Phase 1/2· 23andMe, Inc.· Source

• Active, not recruiting

  Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

  NCT05112237· Tenaya Therapeutics· Source

• Active, not recruiting

  Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

  NCT04624230· Phase 3· Pfizer· Source

• Recruiting

  Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

  NCT05003986· Phase 2· Travere Therapeutics, Inc.· Source

• Enrolling by invitation

  Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy

  NCT04628585· Phase 3· Genetix Biotherapeutics Inc.· Source

• Recruiting

  Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study

  NCT04338048· Children's Hospital of Philadelphia· Source

• Recruiting

  TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  NCT02693535· Phase 2· American Society of Clinical Oncology· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Sickle cell disease2 recruiting
• Childhood cancers1 recruiting
• Congenital heart disease1 recruiting
• Cystic fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Multiple myeloma1 recruiting
• Polycystic kidney disease1 recruiting
• Thalassaemia1 recruiting

Closed trials

• Completed

  A Study to Learn About Sickle Cell Disease In Adult Patients

  NCT05407805· Pfizer· Source

• Completed

  A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

  NCT04238819· Phase 1/2· Eli Lilly and Company· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Phase 2· Pfizer· Source

• Completed

  Community Health Workers and mHealth for Sickle Cell Disease Care

  NCT03648710· Children's Hospital of Philadelphia· Source

• Completed

  Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

  NCT03376438· Edgar Jaeggi· Source

• Terminated

  Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

  NCT02859896· Phase 3· Sanofi· Source

• Completed

  A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  NCT02723994· Phase 2· Incyte Corporation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Narcolepsy3 works · 0 trials